Oxford BioMedica Report Encouraging New Phase II Trial Results with Trovax® in Prostate Cancer

Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces encouraging new data from its first Phase II trial of TroVax in prostate cancer. TroVax is Oxford BioMedica’s lead cancer immunotherapy product, which is being developed in collaboration with sanofi-aventis. The Phase II data were presented by the clinical investigators from the Methodist Hospital in Houston, Texas, at the 6th International Symposium on Targeted Anticancer Therapies on 20 March 2008 in Bethesda, Maryland. This event was organised by the NDDO Research Foundation in a partnership with the US National Cancer Institute (NCI; www.cancer.gov) and the European Society for Medical Oncology (ESMO; www.esmo.org).

In the Phase II trial, 27 patients with metastatic hormone-refractory prostate cancer (HRPC) were treated with TroVax alone (n=14) or TroVax in combination with GM-CSF (n=13). TroVax was well tolerated with no related serious adverse events. Eligibility for the trial included patients with progressive disease and pre-treatment with at least one course of chemotherapy. Of 24 evaluable patients, all mounted robust antibody responses against the targeted tumour antigen, 5T4, and nine patients also showed strong 5T4-specific T-cell responses. Twenty patients (83%) experienced disease stabilisation. The duration of disease stabilisation in patients continues to be assessed and currently ranges from two to more than ten months. As in previous trials of TroVax, the anti-tumour immune response induced by TroVax correlated with clinical benefit. Time to disease progression (TTP) was significantly greater in 5T4-specific T-cell responders compared to non-responders, with a median TTP of 5.6 months versus 2.3 months (p = 0.028). The combination of GM-CSF with TroVax showed similar clinical and immunological responses to TroVax alone.

The principal investigator conducting the trial concluded that the high frequency of 5T4-specific immune responses and the correlation with enhanced TTP are encouraging and warrant further investigation. The same clinical team at the Methodist Hospital has initiated a further Phase II trial of TroVax in approximately 60 patients with HRPC. The trial is randomised and is designed to evaluate TroVax in combination with sanofi-aventis’ Taxotere® (docetaxel) as first line therapy versus docetaxel alone. Patients who progress on docetaxel alone will then be treated with TroVax. For more information on this and
other ongoing and planned trials, see www.oxfordbiomedica.co.uk/trovax.htm.

Dr Mike McDonald, Oxford BioMedica’s Chief Medical Officer, commented on the new data: “We continue to be encouraged by the clinical data from ongoing trials of TroVax. It is particularly reassuring to see the relationship between the antigen-specific immune response induced by TroVax and clinical benefit in a third tumour type, following similar conclusions in trials in renal and colorectal cancer. We are delighted that the clinical team at the Methodist Hospital are supporting further development of TroVax in this setting. With our partner, sanofi-aventis, we believe that TroVax could play an important role in the treatment of prostate cancer, addressing a significant unmet need for patients.”

Oxford BioMedica Plc

Oxford BioMedica Plc
Immunotherapy development

Latest News

Baxter Announces Acquisition of Cheetah Medical

Baxter International Inc., a leading global medical products company, today entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies

Zipline announces positive results from two significant clinical studies

ZipLine Medical, Inc. has announced publication of positive results from two significant clinical studies in two peer- reviewed journals demonstrating that use of Zip® Surgical Skin Closure leads to better clinical outcomes and healthcare cost savings than do surgical staples

Valneva reports strong operational performance and major corporate progress with H1 2019 results

Valneva has reported that its H1 2019 results are marked by strong operational performance and major corporate progress; regaining control of key R&D assets and strengthening its financial outlook with $23 million CEPI chikungunya grant

Valneva initiates second Phase II study for its Lyme Disease vaccine candidate

Valneva has announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15

Valneva reports successful outcome of Phase 2 run-in for its Lyme disease vaccine candidate

Valneva SE has announced progress of its ongoing Phase 2 study for its leading, unique Lyme disease vaccine candidate, VLA15, into the main study phase

New data further validates Breast Cancer Index ability to predict extended endocrine therapy benefit

Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index that further validates its ability to accurately predict which women with early-stage, hormone receptor positive breast cancer will benefit from extended endocrine therapy